Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer
NCT05660954Phase 2Completed
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- May 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in differentiated thyroid cancer (DTC), sponsored by Spanish Group of Neuroendocrine Tumors. Started May 2023; status: completed.
02
Drugs
cabozantinib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT05660954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05660954.